{"links":{"html":"https://www.erudio.com/reports/moonrise-3-nct06919965","json":"https://www.erudio.com/reports/moonrise-3-nct06919965.json","markdown":"https://www.erudio.com/reports/moonrise-3-nct06919965.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"moonrise-3-06919965"}},"request":"https://www.erudio.com/contact?report=moonrise-3-06919965"},"offer":{"cited_commentary_sources":9,"verified_hcp_statements":122,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI. For scientific and insight use inside the organization, not for promotional targeting or outreach. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":750,"identity_verified_people":6,"optional":true,"price_per_verified_person_usd":15,"price_usd":90,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"moonrise-3-nct06919965"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=moonrise-3-06919965","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/moonrise-3-nct06919965","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-19T11:49:14.936338Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":1},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Disease-free Survival (DFS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":16,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":3,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":7,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":3,"title":"Safety and tolerability"},{"claim_count":4,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":11,"coverage":"discussed","id":"A1","source_count":5,"title":"Earlier-phase promise and conditional future impact"},{"claim_count":12,"coverage":"discussed","id":"A2","source_count":2,"title":"Does FGFR selection favor TAR-210 over other local options?"},{"claim_count":18,"coverage":"discussed","id":"A3","source_count":2,"title":"Cystectomy counseling and uncertainty after multiple prior treatments"},{"claim_count":17,"coverage":"discussed","id":"A4","source_count":3,"title":"Local versus systemic treatment, tentative alternative rankings and selective immune-therapy exceptions"},{"claim_count":12,"coverage":"discussed","id":"A5","source_count":5,"title":"Papillary-only approval needs, access and multidisciplinary support"}],"counts":{"cited_sources":9,"claims_by_expression_type":{"comparison":13,"experience":5,"interpretation":19,"opinion":14,"question":12,"restatement":20,"uncertainty":13,"unspecified":26},"claims_by_kind":{"attributed_opinion":4,"interpretation":2,"limitation":6,"source_observation":110},"clinician_statements":76,"evidence_units":61,"findings":7,"people_cited":9,"people_identity_verified":6,"people_total":9,"screened_sources":10,"verified_claims":122},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":0,"questions":6,"restated":4,"views":3},"has_counterview":true,"limitations":2,"links":{"context":0,"support":14},"ma_question":true,"named_voices":3,"passages":6,"sources":2,"sources_by_kind":{"media":2}},"title":"A strong preference for TAR-210 did not resolve its comparative value in FGFR-altered disease"},{"id":"F2","structure":{"claims":18,"claims_by_group":{"comparisons":1,"experience":3,"questions":4,"restated":5,"views":5},"has_counterview":true,"limitations":4,"links":{"context":7,"support":18},"ma_question":true,"named_voices":4,"passages":9,"sources":2,"sources_by_kind":{"media":2}},"title":"Bladder preservation remained conditional on surgical counseling, disease risk and prior-treatment uncertainty"},{"id":"F3","structure":{"claims":17,"claims_by_group":{"comparisons":3,"experience":0,"questions":3,"restated":5,"views":6},"has_counterview":true,"limitations":6,"links":{"context":3,"support":20},"ma_question":true,"named_voices":4,"passages":14,"sources":3,"sources_by_kind":{"media":3}},"title":"Local-treatment preferences did not establish a ranking or eliminate a systemic role"},{"id":"F4","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":4,"views":3},"has_counterview":false,"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":3,"passages":7,"sources":5,"sources_by_kind":{"commentary":2,"media":3}},"title":"Earlier-phase activity generated optimism, with explicit warnings against treating it as Phase 3 confirmation"},{"id":"F5","structure":{"claims":9,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":5,"views":1},"has_counterview":false,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":5,"passages":7,"sources":6,"sources_by_kind":{"commentary":3,"media":3}},"title":"Randomization was valued as a response to the papillary-only evidence and approval gap"},{"id":"F6","structure":{"claims":15,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":7,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":15},"ma_question":true,"named_voices":3,"passages":8,"sources":4,"sources_by_kind":{"commentary":1,"media":3}},"title":"Risk, BCG-response categories and molecular eligibility were separate sources of selection uncertainty"},{"id":"F7","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":4,"views":3},"has_counterview":true,"limitations":2,"links":{"context":2,"support":12},"ma_question":true,"named_voices":3,"passages":7,"sources":4,"sources_by_kind":{"media":4}},"title":"Access and multidisciplinary support could matter as much as the availability of another option"}],"medical_affairs_question":"What evidence would distinguish biomarker-associated activity from greater benefit specifically attributable to selecting TAR-210 over non-targeted intravesical alternatives?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Biomarker-directed enthusiasm stopped short of comparative superiority"},{"id":"section-2","level":2,"title":"Bladder preservation did not remove the surgical benchmark"},{"id":"section-3","level":2,"title":"Local-treatment preferences did not establish a ranking or eliminate a systemic role"},{"id":"section-4","level":2,"title":"Earlier-phase promise remained explicitly conditional"},{"id":"section-5","level":2,"title":"Randomization addressed a papillary-only development gap"},{"id":"section-6","level":2,"title":"Shared definitions helped, but did not eliminate selection uncertainty"},{"id":"section-7","level":2,"title":"Access and collaboration qualified the expanding choice"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T1","label":"Primary endpoint: Disease-free Survival (DFS)"},{"findings":[],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":15},{"id":"F7","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F5","shared_claims":4},{"id":"F6","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-19T11:49:14.936338Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-19T12:43:09Z","record_hash":"b46748bc3ca07b3691709aed8498635e204a948a141e765ab201c12a64d7f544","release_hash":"c536c61917df22bdf6fb3347a134fef73e733231741258adb676cb74f8da4445","report_id":"erudio-nct06919965","run_id":"fbf79a67-7d6e-4816-82f5-88141c08160f","schema_version":"5.0","slug":"moonrise-3-06919965","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"MoonRISe-3 asks whether bladder-delivered TAR-210 improves disease-free survival over intravesical chemotherapy in FGFR-altered, high-risk papillary non-muscle-invasive bladder cancer after BCG. Clinicians in the sources reviewed for this edition express optimism about TAR-210's potential, while expectations remain conditional. Earlier-phase activity and randomization are welcomed, while patient selection draws scrutiny. Comparative benefit remains unresolved, alongside questions about how to identify appropriate patients for TAR-210 and interpret their risk after BCG.","meta_description":"10 sources screened · 122 verified statements (76 from speakers with a confirmed clinical role) from 9 sources · 7 findings. Updated Oct 19, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-f3b0a7de835d8db67eb2-ab0dc616","claim-f3b0a7de835d8db67eb2-f12529b8"],"id":"F5","paraphrase":"A podcast interview explores what kind of clinical evidence could support treatment approvals for papillary-only bladder cancer after BCG.","publication_caveats":["Approval and recruitment descriptions reflect the interview period and should not be read as current status."],"source_channel":"podcast","source_date":"2025-11-15","title":"Randomization was valued as a response to the papillary-only evidence and approval gap"},{"cited_claim_ids":["claim-86f7f4febc8f109b1010","claim-197d0f0d1ad922f8d86b"],"id":"F6","paraphrase":"A podcast interviewer asks how risk groups and BCG-response categories are defined for non-muscle-invasive bladder cancer.","publication_caveats":["The full trial protocol was not available in the sources reviewed for this edition; the discussion does not establish an individual patient's trial eligibility."],"source_channel":"podcast","source_date":"2025-11-15","title":"Risk, BCG-response categories and molecular eligibility were separate sources of selection uncertainty"}]},"publication":{"approved_at":"2026-10-19T12:43:09Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":10},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","Out of scope: 3 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.","188 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed provide qualitative views, not a representative estimate of HCP agreement, treatment use or patient outcomes.","Podcast and video coverage overlaps for the March 2026-published educational session; source totals must not be interpreted as independent clinician totals.","Discussions using unnamed references or different wording may be absent. Two relevant passages were not fully assessed; additional views and qualifications concerning treatment alternatives, toxicity, patient selection and evidence limitations may be missing.","No full protocol or results publication for NCT06919965 was available among the reviewed materials. The report cannot independently assess all eligibility details, endpoint definitions or comparative results.","Earlier TAR-210 recurrence estimates came from separate source accounts and were explicitly preliminary; their numerical differences cannot be reconciled from these statements.","Some connected post-BCG counseling discussions did not state FGFR status. Other alternative-treatment opinions expressly concerned BCG-refractory CIS. These discussions inform the treatment decision but do not demonstrate eligibility for, or efficacy in, MoonRISe-3.","Joanna Sadowska Aka Dr Jojo's individual identity is unverified and the sources reviewed do not establish a clinical role. Félix Guerrero-Ramos's individual identity is also unverified.","Exact TAR-210 and mitomycin C labels were not available among the reviewed materials. Speakers' approval, availability and geographic-access remarks are not a current labeling or reimbursement assessment. The case presenter's TAR-200 availability statement was relative to the presentation, not evidence of current access in every country.","Source publication dates do not establish the date of every session, readout or recruitment milestone, and do not by themselves demonstrate a change of mind."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":3,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":9},"count":9,"evidence_window":{"end":"2026-05-17","start":"2025-04-28"},"retrieval_snapshot":"2026-10-19T09:15:11.771385Z","timeline":[{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2026-W12"},{"count":2,"week":"2026-W13"},{"count":2,"week":"2026-W20"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06919965:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06919965:context","quote_policy":"short_quote_link_out"},{"id":"openfda:e11eeff7-bcaf-4bf1-8da8-88138e01af84:20260727","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-qruug7oeenalz3pi4mk7gini-3mhdjo55ues27","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7ef721","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:aac177","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ed2ebd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916902794814230690:bfd7a205-1f8f-4b55-9fac-81faad08fae8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056007677411487946:7272bc83-1b6d-4b57-a366-fa38ac7e3886","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056010553470943276:63017840-32ea-4e59-8b5e-a164beac6f33","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056043240428617845:9ff28f8b-801e-4bd2-9600-9b172c7ecd66","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:7jy6uqBnwlA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:G79mZpsUuyE","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":4,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":10},"count":10,"evidence_window":{"end":"2026-05-17","start":"2025-04-28"},"retrieval_snapshot":"2026-10-19T09:15:11.771385Z","timeline":[{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2026-W12"},{"count":2,"week":"2026-W13"},{"count":3,"week":"2026-W20"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: tar-210","status":"unmapped"},{"reason":"Unmapped registry intervention: mitomycin c","status":"unmapped"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"}],"indications":[{"reason":"Unmapped registry condition: Non-Muscle Invasive Bladder Neoplasms","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"MoonRISe-3","aliases":["MoonRISe-3","A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)"],"brief_title":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Muscle Invasive Bladder Neoplasms"],"enrollment":{"count":220,"type":"ESTIMATED"},"interventions":[{"name":"TAR-210","synonyms":["JNJ-42756493"],"type":"DRUG"},{"name":"Mitomycin C","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Gemcitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06919965","official_title":"A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-04-06","type":"ESTIMATED"},"primary_endpoints":[{"description":"DFS is measured as the time from randomization to the date of the first recurrence of HR-NMIBC (high-grade Ta, any T1 or carcinoma in situ \\[CIS\\]), progression, or death due to any cause, whichever occurs first.","measure":"Disease-free Survival (DFS)","timeFrame":"Up to 5 years"}],"registry_last_updated":"2026-09-28","registry_url":"https://clinicaltrials.gov/study/NCT06919965","short_name":"MoonRISe-3","short_name_basis":"registry_acronym","sponsor":"Janssen Research & Development, LLC","start_date":{"date":"2025-09-10","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"42756493BLC3005","type":"sponsor_study_id"},{"domain":"EUCT number","id":"2024-519493-39-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}